Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (HK:6990) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has announced that their new drug application for Sacituzumab Tirumotecan (sac-TMT) has been accepted by China’s National Medical Products Administration, following positive results in a pivotal study for treating non-small cell lung cancer. The drug, which has shown significant improvements in treatment outcomes over docetaxel, is also set for a priority review. Investors are cautioned as the drug’s development and commercialization are not guaranteed.
For further insights into HK:6990 stock, check out TipRanks’ Stock Analysis page.